Azurity Pharma Inc v. Alkem Laboratories Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Azurity Pharmaceuticals, Inc. (Delaware)
  • Defendant: Alkem Laboratories Ltd. (Republic of India)
  • Plaintiff's Counsel: Potter Anderson & Corroon LLP
• Case Identification: 1:25-cv-00563, D. Del., 08/12/2026
• Venue Allegations: Venue is asserted based on Defendant being a foreign corporation not residing in any U.S. judicial district. Personal jurisdiction is alleged based on Defendant's continuous business contacts with Delaware, including prior patent litigation in the district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's ZONISADE® (zonisamide) oral suspension constitutes an act of patent infringement.
• Technical Context: The technology concerns stable, oral liquid suspension formulations of zonisamide, an anticonvulsant drug used for treating seizures, intended for patients who have difficulty swallowing solid dosage forms.
• Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendant's notice letter of March 21, 2025, which advised of its filing of ANDA No. 220352. The patents-in-suit are listed in the U.S. Food and Drug Administration's "Orange Book" as covering Plaintiff's ZONISADE® product.

Case Timeline

Date	Event
2017-08-19	Earliest Priority Date for all Patents-in-Suit
2022-10-25	U.S. Patent No. 11,478,456 Issued
2022-12-20	U.S. Patent No. 11,529,333 Issued
2025-03-21	Defendant's ANDA Notice Letter Sent to Plaintiff
2025-12-09	U.S. Patent No. 12,491,179 Issued
2026-07-21	U.S. Patent No. 12,685,723 Issued
2026-08-12	Complaint Filed
2038-08-18	Expiration Date of Patents-in-Suit

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,478,456 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 11,478,456, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued October 25, 2022 (the "'456 Patent").

The Invention Explained

• Problem Addressed: The patent's background section notes that the anticonvulsant drug zonisamide is available in solid oral dosage forms like capsules and tablets, but certain patients, such as children and the seriously ill, are unable to swallow them ʼ456 Patent, col. 3:1-4 This creates a need for an alternative formulation.
• The Patented Solution: The invention provides a stable and palatable oral liquid suspension of zonisamide ʼ456 Patent, abstract The formulation uses a combination of pharmaceutically acceptable excipients-including specific suspending agents, buffering agents, preservatives, and sweeteners-to create a ready-to-use liquid product that is both physically stable and acceptable to patients ʼ456 Patent, col. 4:15-24 ʼ456 Patent, col. 8, Table 1
• Technical Importance: This technology makes zonisamide therapy accessible to patient populations who cannot use solid oral dosage forms, potentially improving treatment adherence and outcomes.

Key Claims at a Glance

• The complaint asserts infringement of at least one claim Compl. ¶16 Independent claim 17 is a representative composition claim.
• Essential elements of Independent Claim 17:
  • A liquid oral pharmaceutical suspension comprising zonisamide at about 20 mg/mL.
  • Xanthan gum at about 3.5 mg/mL.
  • A combination of microcrystalline cellulose and sodium carboxymethylcellulose at about 20 mg/mL.
  • Sodium benzoate at about 1.0 mg/mL.
  • Buffering agents comprising citric acid monohydrate and tri-sodium citrate dihydrate.
  • Sweetening and flavoring agents, and purified water.

U.S. Patent No. 11,529,333 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 11,529,333, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued December 20, 2022 (the "'333 Patent").

The Invention Explained

• Problem Addressed: The patent addresses the same problem as the '456 Patent: the lack of a suitable liquid oral formulation of zonisamide for patients unable to swallow solid forms ʼ333 Patent, col. 3:1-4
• The Patented Solution: The invention describes a liquid oral suspension of zonisamide designed for improved stability and palatability ʼ333 Patent, abstract It specifies a combination of suspending agents (xanthan gum and a cellulose combination), a buffering system, and a preservative to achieve a target pH range and maintain stability over time, as demonstrated by impurity testing data in the specification ʼ333 Patent, col. 4:47-60 ʼ333 Patent, col. 9, Table 2
• Technical Importance: The invention provides a specific formulation recipe aimed at achieving long-term chemical and physical stability, a critical attribute for a commercial liquid pharmaceutical product.

Key Claims at a Glance

• The complaint asserts infringement of at least one claim Compl. ¶20 Independent claim 1 is a representative composition claim.
• Essential elements of Independent Claim 1:
  • A liquid oral pharmaceutical suspension with zonisamide at about 20 mg/mL.
  • A suspending agent comprising about 2 to 3.5 mg/mL of xanthan gum and about 20 mg/mL of a microcrystalline cellulose/sodium carboxymethylcellulose combination.
  • One or more buffering agents.
  • A preservative.
  • The suspension must have a pH of 3.5 to 5.0.
  • The composition must be stable for at least 6 months when stored at 40°C and 25% relative humidity.

U.S. Patent No. 12,491,179 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 12,491,179, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued December 9, 2025 (the "'179 Patent").
• Technology Synopsis: The patent addresses the need for a liquid oral form of the anticonvulsant zonisamide for patients who cannot swallow solid dosage forms ʼ179 Patent, col. 3:1-11 It discloses a stable aqueous suspension comprising zonisamide and specific excipients, including buffering agents (citric acid monohydrate and trisodium citrate dihydrate) and preservatives (sodium benzoate), to achieve a specific pH and impurity profile for long-term stability ʼ179 Patent, abstract ʼ179 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of at least one claim Compl. ¶24 Independent claim 1 is representative.
• Accused Features: The accused instrumentality is Alkem's proposed generic zonisamide oral suspension, which is the subject of ANDA No. 220352 Compl. ¶1 Compl. ¶48

U.S. Patent No. 12,685,723 - "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof"

• Patent Identification: U.S. Patent No. 12,685,723, "Oral Pharmaceutical Composition Comprising Zonisamide and Process of Preparation Thereof," issued July 21, 2026 (the "'723 Patent").
• Technology Synopsis: The patent addresses the need for a liquid oral zonisamide formulation for patients unable to swallow pills ʼ723 Patent, col. 3:1-11 The invention is a liquid oral suspension containing zonisamide as the sole active ingredient, a specific dual-component suspending system, buffering agents, and a preservative, all formulated to achieve a pH between 3.5 and 5.0 and exhibit a total impurity level of 0.10% or less after one month of storage at 40°C ʼ723 Patent, abstract ʼ723 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of at least one claim Compl. ¶28 Independent claim 1 is representative.
• Accused Features: The accused instrumentality is Alkem's proposed generic zonisamide oral suspension, which is the subject of ANDA No. 220352 Compl. ¶1 Compl. ¶53

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is the generic drug product described in Alkem's Abbreviated New Drug Application (ANDA) No. 220352, which seeks FDA approval to market a generic version of Azurity's ZONISADE® product (the "Alkem ANDA Product") Compl. ¶29

Functionality and Market Context

• The complaint alleges that by filing its ANDA, Alkem has represented to the FDA that its product is a zonisamide oral suspension that has the same active ingredient, dosage form, strength, and route of administration as ZONISADE® Compl. ¶35
• The Alkem ANDA Product is intended for use as an adjunctive therapy for the treatment of partial onset seizures, mirroring the indication for ZONISADE® Compl. ¶11 Compl. ¶35
• The complaint alleges that Alkem intends to engage in the commercial manufacture, use, and sale of the Alkem ANDA Product promptly upon receiving FDA approval, positioning it as a direct generic competitor to Azurity's branded product Compl. ¶33
• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that by filing its ANDA, Alkem seeks approval for a drug product that, if commercially manufactured and sold, would infringe the patents-in-suit Compl. ¶38 The infringement theory is predicated on the allegation that to be bioequivalent to ZONISADE®, the Alkem ANDA Product must necessarily possess the formulation characteristics claimed in the patents.

'456 Patent Infringement Allegations

Claim Element (from Independent Claim 17)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
zonisamide in an amount of about 20 mg/mL	The Alkem ANDA Product is alleged to contain the same active ingredient at the same strength as ZONISADE®, which is covered by the patent.	¶35	col. 8:Table 1
xanthan gum in an amount of about 3.5 mg/mL	The Alkem ANDA Product is alleged to have a formulation that meets this limitation to achieve bioequivalence.	¶35; ¶39	col. 8:Table 1
a combination of microcrystalline cellulose and sodium carboxymethylcellulose in an amount of about 20 mg/mL	The Alkem ANDA Product is alleged to have a formulation that meets this limitation to achieve bioequivalence.	¶35; ¶39	col. 7:20-24
sodium benzoate in an amount of about 1.0 mg/mL	The Alkem ANDA Product is alleged to have a formulation that meets this limitation to achieve bioequivalence.	¶35; ¶39	col. 13:5-6
one or more buffering agents comprising citric acid monohydrate and tri-sodium citrate dihydrate	The Alkem ANDA Product is alleged to have a formulation that meets this limitation to achieve bioequivalence.	¶35; ¶39	col. 8:Table 1

'333 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
zonisamide in an amount of about 20 mg/mL	The Alkem ANDA Product is alleged to contain the same active ingredient at the same strength as ZONISADE®.	¶35	col. 8:Table 1
a suspending agent comprising about 2 mg/mL to about 3.5 mg/mL xanthan gum and about 20 mg/mL of a combination of microcrystalline cellulose and sodium carboxymethylcellulose	The Alkem ANDA Product is alleged to utilize this specific suspending agent system to achieve the required physical properties and bioequivalence.	¶35; ¶44	col. 8:Table 1
wherein the liquid oral pharmaceutical suspension has a pH of 3.5 to 5.0	The Alkem ANDA Product is alleged to be formulated to this pH range to ensure stability and bioequivalence.	¶35; ¶44	col. 5:19-20
wherein the composition is stable for at least 6 months when stored at 40° C. and 25% relative humidity	The Alkem ANDA Product is alleged to meet this stability profile, as would be required for FDA approval of a bioequivalent generic.	¶35; ¶44	col. 9:Table 2

• Identified Points of Contention:
  • Formulation Design: A primary question is whether Alkem's ANDA product achieves bioequivalence using the specific combination and concentrations of excipients claimed in the patents, or if it uses a different, non-infringing formulation. The defense may argue that alternative formulations can achieve the same therapeutic effect.
  • Scope Questions: The interpretation of the term "about" in the claims' concentration limitations will be critical. The dispute will likely focus on whether the concentrations used in the Alkem ANDA Product fall within the range implied by "about."
  • Technical Questions: For claims with functional limitations, such as the stability requirement in the '333 Patent, a key question will be what evidence the ANDA contains regarding the product's performance. Infringement will depend on whether Alkem's own data demonstrates that its product meets these stability criteria.

V. Key Claim Terms for Construction

The Term: "about"

• Context and Importance: This term appears in nearly all independent claims in relation to the concentration of the active ingredient and key excipients. Its construction will be central to the literal infringement analysis. Whether a formulation with a slightly different concentration (e.g., 19.5 mg/mL of zonisamide) infringes will depend entirely on the scope afforded to "about."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term itself implies some degree of numerical flexibility. The patents' use of "about" suggests the inventors did not intend to be limited to the exact values recited.
  • Evidence for a Narrower Interpretation: The specifications provide examples with highly precise values (e.g., "20.00 mg/ml") ʼ456 Patent, col. 8, Table 1 A defendant may argue that "about" should be construed narrowly to cover only minor variations attributable to standard manufacturing tolerances around these specific examples.

The Term: "suspending agent"

• Context and Importance: Claim 1 of the '333 Patent recites a "suspending agent comprising" both xanthan gum and a cellulose combination. Practitioners may focus on this term because the infringement determination rests on whether Alkem's product uses this specific two-part system as its "suspending agent." If Alkem's ANDA characterizes these components differently (e.g., one as a suspender and one as a stabilizer), it could create a dispute.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes suspending agents as compounds added to "increase the viscosity of the solution, which is necessary to prevent sedimentation" ʼ333 Patent, col. 4:47-50 Azurity may argue that any component contributing to this function is part of the "suspending agent."
  • Evidence for a Narrower Interpretation: Alkem may argue that the term should be limited to the primary component responsible for suspension, and that other ingredients are merely ancillary "thickeners" or "stabilizers," thus falling outside the claim's requirement that the "suspending agent" itself comprises both materials.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Alkem will indirectly infringe by inducing infringement Compl. ¶39 Compl. ¶44 This allegation is based on the future act of selling the Alkem ANDA Product with a label that will instruct physicians and patients to use the drug for its approved indication, which is allegedly covered by the patents.
• Willful Infringement: The complaint alleges that Alkem had "actual and constructive knowledge" of the patents-in-suit prior to filing its ANDA and knew the filing constituted an act of infringement Compl. ¶40 Compl. ¶45 Compl. ¶50 Compl. ¶55 This alleged pre-suit knowledge forms the basis of the claim for willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of formulation equivalence: Will discovery show that to achieve bioequivalence with ZONISADE®, Alkem's ANDA product necessarily adopted the specific combination and concentrations of excipients (e.g., the dual suspending agents, specific buffers) recited in the asserted claims, or did Alkem develop a therapeutically equivalent but non-infringing formulation?
• The case will also likely hinge on a question of definitional scope: How broadly will the court construe the term "about" as it applies to the claimed concentrations? The resolution of this issue could determine infringement for multiple claim limitations across all asserted patents.
• A key evidentiary question will be one of functional performance: For claims that include stability requirements, such as in the '333 and '723 patents, does the data within Alkem's confidential ANDA submission demonstrate that its product in fact meets these claimed stability and impurity profiles? Infringement of these claims will depend on the technical data, not just the list of ingredients.